Please login to the form below

Not currently logged in
Email:
Password:

pharma merger

This page shows the latest pharma merger news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Crunch time for Brexit, GSK CEO RSVP from Trump

Daily Brief: Crunch time for Brexit, GSK CEO RSVP from Trump

A round up from pharma, biotech and healthcare. Theresa May looks to enforce ‘soft’deal on ‘hard’Brexiteers. ... Takeda to sell Osaka HQ to help cover Shire costs. Takeda’s $63bn purchase of Shire is the biggest pharma merger for some years,

Latest news

  • Shire warms to Takeda’s latest offer, extending deadline Shire warms to Takeda’s latest offer, extending deadline

    Analysts suggest however that negative sentiment could still scupper a deal that is by far the largest ever undertaken by the company - and the biggest in pharma since the $70bn ... Allergan merger in 2015.

  • Pfizer could raise ‘up to $15bn’ from consumer unit sale Pfizer could raise ‘up to $15bn’ from consumer unit sale

    of failed merger attempts with AstraZeneca and Allergan, the takeovers of Hospira and cancer specialist Medivation, and the divestment of Hospira’s infusions unit. ... been persistent speculation that it is still looking to complete a mega-merger with

  • Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A

    Investors call on the pharma giant to consider a large merger or acquisition deal. ... Pfizer walked away from a $160bn merger with Allergan last year, blaming a clampdown on so-called tax inversion deals.

  • US tax changes claim Pfizer scalp as Allergan deal abandoned US tax changes claim Pfizer scalp as Allergan deal abandoned

    The mega-merger would have created the world's largest pharma company, valued at around $330bn, but relied on the US firm benefiting from Ireland's lower corporate tax rate. ... While in a statement the White House said the new rules were not calculated

  • Baxalta agrees to $32bn Shire takeover Baxalta agrees to $32bn Shire takeover

    Shire said the post-merger firm will be able to deliver double-digit sales growth to more than $20bn by 2020, with around two-thirds of its turnover coming from rare ... Pharma companies are increasingly drawn to rare diseases as they can generally

More from news
Approximately 2 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    For an indepth analysis of these deals, read'Pharma deals during March 2014'. ... Vidara Therapeutics/. Horizon Pharma. Merger/ acquisition. Actimmune (interferon gamma-1b) for CGD and SMO (approved).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Reig Jofre boosts Forté Pharma’s senior team Reig Jofre boosts Forté Pharma’s senior team

    Reig Jofre boosts Forté Pharma’ s senior team. Appoints Alain Boutboul as the nutritional supplements group’s general manager. ... Ignasi Biosca, chief executive officer, Reig Jofre, said: “We had been working for some time on Forté Pharma's

  • Vifor Pharma appoints Dario Eklund Vifor Pharma appoints Dario Eklund

    Vifor Pharma has named Dario Eklund as their head of international business operations. ... Prior to that, he was general manager of Switzerland for Aventis Pharma, until its 2004 merger with Sanofi, and earlier in his career he held a number of

  • Merck & Co appoints new financial head Merck & Co appoints new financial head

    Kellogg had been in the position since joining Merck in 2007 and played a key role in the pharma company's merger with Schering-Plough.

  • Cipher names Gerald McDole as chair Cipher names Gerald McDole as chair

    Cipher has appointed pharma veteran Gerald McDole as chair of the board of directors. ... Prior to this he was president and CEO of Astra Pharma in Canada before its merger with Zeneca.

  • Merck Serono appoints chief medical officer Merck Serono appoints chief medical officer

    Dr Steven Hildemann has left the US-based Merck &Co to join its German namesake Merck KGaA as chief medical officer of its pharma business Merck Serono. ... He joined Merck &Co after the US pharma giant merger with his former company, Schering-Plough, in

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics